Apogee Therapeutics (APGE)

• Market cap: $4.95B
• 1 day: -2.19%
• 5 days: -1.61%
• 1 month: 6.08%
• 3 months: -6.39%
• 6 months: 95.06%
• Year to date: -5.12%
• 1 year: 87.58%
• 5 years: 238.67%
• 10 years: 238.67%
• Sector: Healthcare
• Industry: Biotechnology

About: Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Employees: 261